Journey Medical Corp (DERM): Cash & Equivalents
$24.09M
As of 2025-12-31
$25.64M
As of 2026-06-30
-9.0%
3-year compound annual growth
+23.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.09M | +18.6% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $20.30M | -26.0% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $27.44M | -14.3% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $32.00M | -34.8% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $49.08M | +495.2% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $8.25M | n/a | 2022-03-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Journey Medical Corp (DERM) | 2025-12-31 | $24.09M | +18.6% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $112.28M | +61.5% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $164.09M | +359.3% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $79.38M | +38.6% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $26.31M | -15.0% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $32.30M | -13.3% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $40.27M | -23.9% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $149.10M | -33.6% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $15.12M | -65.8% |
Compare DERM, TNGX, NUVB, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗